Cyfuse Biomedical K.K. (TYO:4892)
Japan · Delayed Price · Currency is JPY 590.00
+9.00 (1.55%)
May 29, 2026, 3:30 PM JST
Cyfuse Biomedical K.K. Revenue
Cyfuse Biomedical K.K. had revenue of 28.00M JPY in the quarter ending March 31, 2026, with 16.67% growth. This brings the company's revenue in the last twelve months to 234.00M, up 244.12% year-over-year. In the year 2025, Cyfuse Biomedical K.K. had annual revenue of 230.00M with 325.93% growth.
Revenue (ttm)
234.00M
Revenue Growth
+244.12%
P/S Ratio
25.12
Revenue / Employee
10.17M
Employees
23
Market Cap
5.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 230.00M | 176.00M | 325.93% |
| Dec 31, 2024 | 54.00M | -7.00M | -11.48% |
| Dec 31, 2023 | 61.00M | -313.00M | -83.69% |
| Dec 31, 2022 | 374.00M | -334.00M | -47.18% |
| Dec 31, 2021 | 708.00M | 571.00M | 416.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 67.84B |
| Fuso Pharmaceutical Industries,Ltd. | 62.17B |
| Nippon Chemiphar | 33.09B |
| Morishita Jintan | 12.69B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 6.16B |
| WDB coco | 4.82B |
| SymBio Pharmaceuticals | 1.28B |